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The biocompatibilities in blood puriﬁcation therapy are deﬁned as “a concept to stipulate safety of blood puriﬁcation therapy by
anindexbasedoninteractioninthebodyarisingfrombloodpuriﬁcationtherapyitself.”Thebiocompatibilitiesareassociatedwith
not only materials to be used but also many factors such as sterilization method and eluted substance. It is often evaluated based
on impacts on cellular pathways and on humoral pathways. Since the biocompatibilities of blood puriﬁcation therapy in particular
hemodialysisarenotjustaprognosticfactorfordialysispatientsbutacontributoryfactorforlong-termcomplications,itshouldbe
consideredwithadequateattention.Itisimportantthatbloodpuriﬁcationtherapyshouldbeperformedbyconsistentlyevaluating
not only risks associated with these biocompatibilities but also the other advantages obtained from treatments. In this paper, the
biocompatibilities of membrane and adsorption material based on Japanese original which are used for blood puriﬁcation therapy
are described.
1.Introduction
The biocompatibilities in blood puriﬁcation therapy are
deﬁned as “a concept to stipulate safety of blood puriﬁ-
cation therapy by an index based on interaction in the
body arising from blood puriﬁcation therapy itself.” The
biocompatibilities are associated with not only materials
to be used but also sterilization method, eluted substance,
medical agents such as anticoagulant, dialysate solution, and
contamination, and so on. It is often evaluated based on
impacts on cellular pathways such as leukocyte and platelet
a sw e l la so nh u m o r a lp a t h w a y ss u c ha sc o m p l e m e n ts y s t e m ,
coagulation/ﬁbrinolysis system, kallikrein-kinin system, and
cytokine. For hemodialysis the biocompatibilities on blood
puriﬁcation therapy are not just a prognostic factor for
dialysis patients but a contributory factor for long-term
complications such as immunodeﬁciency, cardiovascular
disease, and dialysis-related amyloidosis (DRA). The mate-
rial of dialyzer is roughly classiﬁed into cellulose type
membrane such as cellulose triacetate (CTA) membrane and
synthetic type membrane including polyethersulfone (PES)
membrane, polymethylmethacrylate (PMMA) membrane,
ethylene vinyl alcohol (EVAL) membrane, and vitamin E-
coated polysulfone (PS) membrane.
In this paper, the biocompatibilities of membrane for
dialysis and adsorption material for blood puriﬁcation
therapy which were developed in Japan are described.
2. Cellulose-TypeDialyzer
2.1. Cellulose Triacetate (CTA) Membrane. Cellulose acetate
membrane is a kind of cellulose-type membrane which
is synthesized by a reaction of natural polymer cellulose
and acetic acid, having properties of higher transparency
and toughness among thermoplastics. Cellulose diacetate is
formed by substituting two hydroxyls within cellulose, and
CTA is formed by substituting three hydroxyls (Figure 1). As
the number of substitutions increases, hydrophilic property
ofthemembranedecreasesandcomplementactivationofthe
membrane also decreases, as a result biocompatibility of the
membrane improves.
This membrane is characterized by the thickness of
15μm, the thinnest among commercial dialyzers in Japan,
with a uniform cross-sectional structure (Figure 2)i nw h i c h2 International Journal of Biomaterials
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Figure 1: The structural formula of CTA. CTA is formed by sub-
stituting three hydroxyls within cellulose.
Figure 2: The scanning electron microscopy ﬁndings of cross-
sectional structure of CTA. The cross-sectional structure of CTA
showsuniformstructureinwhichporesizefrominside(bloodside)
to outside (dialysate side) the hollow ﬁber is equal.
pore size from inside (blood side) to outside (dialysate side)
the hollow ﬁber is equal. Compared with those of asymmet-
ric membrane, pore size on dialysate side is relatively smaller
and that on blood side is relatively larger. Therefore, it has a
characteristic that endotoxin-like substances in the dialysate
are hard to permeate from dialysate side.
Since hydroxyl group in cellulose is substituted by acetyl
group in CTA, complement activation by hydroxyl during
d i a l y s i sa sw e l la sv a r i a t i o n si nl e u k o c y t ea n dg r a n u l o c y t e
elastase is infrequently observed. Hydrophilic property of
hemodialysis membrane is prone to activate coagulation
factor, whereas its hydrophobic property brings about strong
reactiononplatelet.PropertyofCTAhaswellbalanceofboth
hydrophilicity and hydrophobicity, and it has been reported
to be excellent in antithrombogenicity [1].
3. Synthetic Membrane Dialyzer
Synthetic type membrane is hydrophobic with a property
to cause thrombosis and coagulation in contact with blood.
Therefore, in case of synthetic membrane, hydrophobic
functional group is substituted by hydrophilic group, or
acrylic acid or polyvinylpyrrolidone (PVP) is used as a
hydrophilizing agent. Possible elution from membrane has
been reported since the PVP is hydrosoluble [2].
3.1. Polyethersulfone (PES) Membrane. PS membrane is
synthesized by polymerizing dichlorodiphenyl sulfone with
bisphenol A, whereas PES is done by polymerizing dichloro-
diphenyl sulfone with dihydroxydiphenyl sulfone (Figure 3).
Therefore, PES has a similar property to that of PS, but, it is
considered as bisphenol A-free membrane [3]. Further, since
PES characteristically has not aliphatic part which exists in
PS and atomic weight ratio of sulfone group is higher
than that of PS, heat resistance, mechanical resistance, and
hydrophilicity are even higher. Moreover, hydrophilicity has
been further enhanced by adopting PVP as a hydrophilizing
agent in the process of PES membrane manufacturing. In
addition, the hydrophilicity based on the PVP exerts anti-
thrombogenicity by inhibiting protein fouling on membrane
surface.
PES membrane is characterized in the cross-section
structure of this membrane (Figure 4). It has an asymmetric
three-layer structure having a compact layer with ﬁne pore
size on the inside and outside of the hollow ﬁber as well as
a support layer in the central part thereof. With a membrane
thickness of 40μm, the mechanical strength of this mem-
brane depends on its support layer in the central part and
the molecule sieving eﬀect of the blood is provided by the
compact layer inside the hollow ﬁber.
Excellent biocompatibility has been reported for PSE-
150D (Nipro Co., Ltd., Osaka, Japan), which adopts PES
membrane, without any signiﬁcant change in leukocyte,
platelet, C3a, and granulocyte elastase observed during dial-
ysis therapy [4]. With equivalent or better biocompatibility
compared with PS membrane, it works more excellently
(Figure 5), in particular, relating to variation in platelet due
to its high hydrophilicity.
3.2. Polymethylmethacrylate (PMMA) Membrane. PMMA
membrane is produced by mixing and solving isotactic
PMMA and syndiotactic PMMA which are diﬀerent in
steric structure. By using PMMA, it is possible to produce
membrane with wide range of pore sizes by changing
conditions including the blend ratio and also it is possible
to produce negatively charged membrane depending on the
types of additive agent to be used. It has adsorptive capacity
and because of negative membrane charge, in particular, it
adsorbs larger amount of basic protein.
PMMA membrane is characterized by the ﬁnding that
cross-section structure of the membrane (Figure 6)h a sa
symmetricstructurehavingnearlyhomogenousmicroscopic
pores from inner surface to outer surface of the hollow
ﬁber. The pore sizes on the inner surface of PMMA are
larger compared with those of PS membrane. Therefore,
PMMA membrane has lower sieving coeﬃcient for beta2-
microglobulin (β2-MG) area than that of PS membrane
but it is excellent in absorptive removal of substances with
molecular weight of β2-MG and those more than 50,000
dalton, which are hard to remove by PS membrane.
PMMA membrane is known for its excellent biocompat-
ibility based on many reports that it causes less cytokine pro-
ductionsuchasTNF-αandNOsynthesis[5].Ithasalsobeen
reported that PMMA membrane adsorbs and removes factor
D which triggers alternative pathway complement activation
[6]. In cases of acute kidney injury, it has been reported that
PMMA membrane with excellent biocompatibility achieves
higher survival rate compared with a case of Cuprophan
(regenerated cellulose) membrane [7].International Journal of Biomaterials 3
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Figure 3: The structural formulas of PES and PS. PS membrane is synthesized by polymerizing dichlorodiphenyl sulfone with bisphenol A,
whereas PES is done by polymerizing dichlorodiphenyl sulfone with dihydroxydiphenyl sulfone. Therefore, PES has similar property to PS,
but risk of bisphenol A elution from membrane material is lower than that of PS.
Figure 4: The scanning electron microscopy ﬁndings of cross-
sectional structure of PES. The cross-section structure of PES has
an asymmetric three-layer structure having a compact layer with
ﬁne pore size on the inside and outside of the hollow ﬁber as well as
a support layer in the central part thereof.
3.3. Ethylene Vinyl Alcohol (EVAL) Membrane. EVAL mem-
brane is produced by solution polymerization between
ethylene and vinyl acetate as well as alkali saponiﬁcation. As
chemical structural formula of EVAL membrane is expressed
that vinyl alcohol group with hydrophilicity and ethylene
group with hydrophobicity are combined at a certain
rate, hydrophilic segment and hydrophobic segment are
associated with solute permeability and mechanical strength,
respectively.
Platelet-neutrophil complex formation is enhanced by
the activations of both platelet and complement which are
triggeredwhenhemodialysismembranecontactswithblood.
Neutrophil activation, such as radical oxygen production,
is triggered by platelet-neutrophil complex [8]. Since these
activations of leukocyte and platelet aﬀect hemorheology,
microcirculatory disorder could be triggered during HD. It
has been reported that impact on leukocyte and platelet
is lower in EVAL membrane compared with that in PS
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Figure 5: The change of WBC and platelet number during
HD session by using PSE-150D (Nipro Co., Ltd., Osaka, Japan)
and PS. Compared with PS, PES has excellent biocompatibility,
in particular, relating to variation in platelet due to its high
hydrophilicity (This ﬁgure is due to Dr. Nii’s kindness.)
membrane or cellulose diacetate membrane [9]. It has also
been reported that microcirculatory disorder is hard to
occur during HD with EVAL membrane due to its excellent
biocompatibility [10].4 International Journal of Biomaterials
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Figure 6: The scanning electron microscopy ﬁndings of cross-
section structure of PMMA. PMMA has a symmetric structure
having nearly homogenous microscopic pores from inner surface
to outer surface of hollow ﬁber.
3.4. Vitamin E-Coated Polysulfone (PS) Membrane. During
hemodialysis session, large amount of antioxidant materials
isconsumedinthebodysincetheneutrophilicactivation,the
radical oxygen production, and the resulting oxidant stress
reach excess states by the blood contact with hemodialysis
membrane [11]. In order to reduce these excess states of
the oxidant stress, following dialysis membrane has been
developed that vitamin E with antioxidant eﬀect is coated on
c e l l u l o s em e m b r a n eo rP Sm e m b r a n e[ 12], and it has been
reported that active oxygen production is suppressed and
that oxidant stress is reduced during hemodialysis [13, 14].
4. Other Blood PuriﬁcationDevices
InJapan,avarietyofadsorptionmaterials,whichmoreselec-
tively remove disease-related substances based on principle
of adsorption, have been developed and applied clinically.
Adsorption materials used for blood puriﬁcation are roughly
divided into blood adsorbent (hemoadsorption column)
for direct hemoperfusion and plasma adsorbent (plasma
adsorption column) for plasma perfusion.
4.1. Hemoadsorption Column
4.1.1. β2-MG Adsorption Column (Lixelle). β2-MG, which
is a hydrophobic protein with molecular weight of 11,800,
is accumulated during long-term dialysis. Further, insoluble
amyloidproteinwhichconsistsprimarilyofβ2-MGwithvar-
ious modiﬁcations is accumulated in organs throughout the
body and it results in a development of amyloidosis (dialysis-
related amyloid (DRA)). DRA causes deterioration in ADL
and QOL of dialysis patients. Accumulation of β2-MG not
only leads ADL and QOL of dialysis patients to deteriorate
but also adversely aﬀects survival. Therefore, HD or HDF
based on high-ﬂux membrane has been performed aiming at
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Figure 7: The schema of the Lixelle column. The Lixelle column is
designed to adsorb β2-MG selectively by combined use of hydro-
phobic interaction and adequate pore size.
removing β2-MG from the body, and ultrapure dialysate and
excellent biocompatible dialyzers have been applied aiming
at inhibiting β2-MG production. Direct hemoperfusion with
β2-MG adsorber column (Lixelle: Kaneka Co., Ltd., Osaka,
Japan) was developed in 1996 which is capable of powerfully
removing β2-MG from the blood [15]. The Lixelle column
contains 350mL of porous cellulose adsorbent beads with
a diameter of about 460μm, in which a hexadecyl group
with high hydrophobicity is used as ligand porous cellulose
adsorbent beads. It incorporates peptides and proteins with
a molecular weight of 4,000 to 20,000 dalton by the molecule
sieving eﬀect of the surface pores of the beads (Figure 7),
whereastotalprotein,albumin,immunoglobulins,andlipids
are not adsorbed [16]. Through the clinical eﬀect of Lixelle,
improvements not only in arthralgia, nocturnal awakening,
and ADL but also in pinch strength and median motor
terminal latency were observed after a year of Lixelle therapy
[17, 18]. In Lixelle, biocompatibility is a crucial issue since
blood is directly perfused through adsorbent. As it has
been reported that HD combined with Lixelle increases
myeloperoxidase and polymorphonuclear leukocyte-elastase
compared with HD not combined with it, further examina-
tions of the biocompatibility are required [19].
4.1.2. Endotoxin Removal Column (Toraymyxin). Ac o l -
umn for directly removing endotoxin from the blood
(Toraymyxin: Toray Industries, Osaka, Japan) was developed
for treatment of endotoxin shock which is one of the
causes of prerenal acute kidney injury [20]. Toraymyxin is
ﬁlled with polymyxin-B-immobilized polystyrene derivative
ﬁbers. Polymyxin B ﬁxed on a ﬁbrous carrier exerts a
functiontoneutralizetheactivityofendotoxinbycombining
with lipid A, which is an active center of the activity
(Figure 8). A new functional mechanism has been reported
for Toraymyxin that it has an eﬀect to adsorb endogenous
cannabinoid which is an early mediator of endotoxin shock
[21]. In patients with septic shock, a lot of clinical eﬀects
of Toraymyxin have been reported, including elevation in
blood pressure, reduction of vasopressor, decrease in 28-day
mortality and hospital mortality, and improvement in organ
failure [22].International Journal of Biomaterials 5
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Figure 8: The schema of toraymyxin. Toraymyxin is ﬁlled with polymyxin-B-immobilized polystyrene derivative ﬁbers. Polymyxin B ﬁxed
on a ﬁbrous carrier exerts a function to neutralize the activity of endotoxin by combining with lipid A, which is an active center of the
activity.
Even though a risk that a possibility of ﬁxed polymyxin B
is eluted cannot be totally excluded, clinically apparent side
eﬀect has not been recognized [23].
4.1.3. Leukocyte Removal Therapy (LRT). LRT is a therapy
to directly remove leukocyte from the blood which is
considered to be related as a cause of disease or symptoms.
There are two types of therapy for the present, that is,
leukocytapheresis (LCAP) and granulocytapheresis (GCAP),
and they have clinical indications for inﬂammatory bowel
disease and rheumatoid arthritis in Japan [24–27].
(1) LCAP. Polyethylene terephthalate (PET) ﬁber with a
diameter of 3μmo rl e s sh a sap r o p e r t yt oa d s o r ba l m o s t
100% of granulocyte and monocyte and 30 to 60% of
lymphocyte and platelet. Cellsorba (Asahi Medical Co.,
Tokyo, Japan) is comprised of a rolled nonwoven fabric of
PET ﬁber with a ﬁber diameter ranging from 0.8 to 2.8μm
for selectively removing leukocyte.
Problems of biocompatibility on PET include bradykinin
shock which occurs in patients who are orally taking
angiotensin-converting enzyme (ACE) inhibitor since PET
is negatively charged. Blood coagulation system is strongly
activated by the blood contacts with a negatively charged
material, and it results in production of bradykinin (BK)
havingvasodilatingaction.ThisBKisinactivatedbykininase
II which is an enzyme identical to ACE. Therefore, the
function of kininase II which is an enzyme identical to
ACE is inhibited by taking ACE inhibitor and it causes
increase in BK concentration in the blood, vasodilatation,
and shock symptom (Figure 9). Besides, some reactions on
the skin of blood return, such as pain, redness, and swelling,
could be brought by various chemical mediators which are
released from active leukocyte and platelet adsorbed within
Cellsorba.
(2) GCAP. Cellulose acetate (CA) beads combine with im-
munoglobulin (IgG) and complement active C3b/C3bi.
Granulocyte and monocyte have receptors for Fc of IgG or
complementandareselectivelytrappedviaimmunoglobulin
and complement which are combined with CA and these
receptors.
Adacolumn (JIMRO, Takasaki, Japan) is a puriﬁer ﬁlled
with 30,000 of CA beads with a diameter of 3mm for
selectively removing granulocyte and monocyte. During the
puriﬁcation,neitherlymphocytenorplateletisremoved.The
complications, which included venous pressure elevation,
venous access diﬃculty, coagulation in blood circuit, and
diﬃcultyinreturningblood,occurredduring2.3%ofGCAP.
However, there were no serious adverse events [28].
4.2. Plasma Adsorption Column
4.2.1. Plasma Adsorption Based on a Principle of Hydrophobic
Bonding (Immusorba PH-350/TR-350). Autoantibody and
immune complex have hydrophobic group. Both phenylala-
nine and tryptophan are hydrophobic amino acids widely
distributed in the body. Immusorba PH-350 (Asahi Medical
Co.,Tokyo,Japan)isusingphenylalanineasaligand,andTR-
350 (Asahi Medical Co., Tokyo, Japan) is using tryptophan as
a ligand. These columns covalently bond with the hydroxyl
group on the surface of porous polyvinyl alcohol gel with
the amino group of amino acid (Figure 10). These columns
could selectively remove autoantibody or immune complex6 International Journal of Biomaterials
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byhydrophobicbonding. Further,astheseadsorbingmateri-
alsarechargednegatively,theaﬃnity betweenligandofthese
columns and antibody was mainly hydrophobic interaction
and was partially caused by the ionic interaction based on
carboxylic group (Figure 11). The clinical eﬀects of these
columns have been reported on lupus nephritis, myasthe-
nia gravis, multiple sclerosis, and other collagen diseases
[29–33].
As both Immusorba PH-350 and TR-350 are charged
negatively, shock symptom is triggered by bradykinin in
patientswhoaretakingACEinhibitor.Inaddition,reduction
in Ca ion level could be observed temporarily during
treatment (Figure 12) because the positive ion could be
absorbed by the negative charge.
4.2.2.PlasmaAdsorptionBasedonElectrostaticBond(Liposor-
ber, Selesorb). Apo-B, anti-DNA antibody, immune com-
plex, or antigen-recognizing site on anticardiolipin antibody
is charged positively. Liposorber (Kaneka Co., Ltd., Osaka,
Japan) and Selesorb (Kaneka Co., Ltd., Osaka, Japan) are
a column, which includes cellulose beads with the negative
charge of dextran sulphate. The aﬃnity between negative
charge of these columns and these positive-charged etiolog-
ical substances was mainly caused by the ionic interaction
(Figure 13). Alternatively, Selesorb is devised to enhance
selectivity of anti-DNA antibody, immune complex, and
anticardiolipin antibody which are smaller than apo-B by
making pore structure of cellulose gel smaller (Figure 14).
As both Liposorber and Selesorb are charged negatively, they
have a risk of developing shock symptom by bradykinin in
patients who are taking ACE inhibitor.
(1) Liposorber. LDL cholesterol level is drastically reduced
by 60 to 80% by single LDL apheresis using Liposorber,International Journal of Biomaterials 7
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The aﬃnity between ligand of these columns and antibody was
mainly hydrophobic interaction and partially caused by the ionic
interaction based on carboxylic group.
300 600 900 1200 1500
Ca++7.4
(mmol/L)
∗∗
∗
Start
Treated plasma volume (mL)
1.3
1.25
1.2
1.15
1.1
1.05
1
0.95
∗∗∗
∗∗∗
∗∗∗
∗ P<0.05
∗∗ P<0.01
∗∗∗ P<0.001
Figure 12: The change of serum Ca ion level during immunoad-
sorption with Immusorba TR-350. Reduction of Ca ion level could
beobservedduringtreatmentbyusingImmusorbaTR-350,because
positive ion could be absorbed by the negative charge.
whereas HDL cholesterol level is hardly reduced. LDL
apheresis using Liposorber is conducted for the hetero-
familial hyperlipidemic patients, and clinical eﬀects have
been reported that incidence of cardiovascular event reduced
by 70% compared with those in groups treated based on
medication alone [34]. Further, the clinical eﬀects of LDL
apheresis using Liposorber have been reported also on
arteriosclerosis obliterans for which hyperlipidemia is one
of the risk factors [35]. The mechanisms are supposed to
have impacts on (i) improvement in viscosity of blood
and plasma, (ii) improvement in erythrocyte deformability,
(iii) increase of vasodilator such as bradykinin and NO,
(ix) reduction in coagulation factor such as ﬁbrinogen,
(x) reduction in cell adhesion factor, (xi) inhibition of
platelet activation, and (xii) inhibition of oxidizability of
LDL. Moreover, the progression of renal dysfunction due
to focal glomerulosclerosis (FGS) which presents refractory
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DL L
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HDL
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Anti-DNA
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Figure 13: The schema of the Liposorber and Selesorb. Apo-
B, anti-DNA antibody, immune complex, or antigen-recognizing
site on anticardiolipin antibody is charged with positive charge.
Liposorber and Selesorb include cellulose beads with the negative
charge of dextran sulphate. The aﬃnity between negative charge of
these columns and these positive charged etiological substances was
mainly caused by the ionic interaction.
nephrotic syndrome to steroids was ameliorated by LDL
apheresis. Glomerular sclerosis is thought to be caused by
systemic or intraglomerular hypertension associated with
arteriosclerosis progress, enhanced cytokine secretion as well
as mesangial cell proliferation associated with increase of
macrophage in glomerulus, and disorder of mesangial cell,
and they are associated with increase of LDL in the blood
[36].
In a multi-institutional study of LDL apheresis using
Liposorber for steroid-resistant nephrotic syndrome, signif-
icant reduction in urine protein and elevation in serum8 International Journal of Biomaterials
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Figure 14: The diﬀerence of between Liposorber and Selesorb. The
pore size of Selesorb beads is smaller than that of Liposorber so that
causative antibodies including anti-DNA antibody are selectively
adsorbed avoiding larger-size molecules such as LDL.
albumin level were recognized which shortened the days
required for reducing urine protein level to less than
3.5g/day. In addition, the following clinical eﬀects have
been also reported that remission rate in two years after
completion of treatment is signiﬁcantly high [37]. This
paper pointed out the following factors for possible mech-
anisms of LDL apheresis using Liposorber: improvement of
hyperlipidemia as well as inhibition of hypercoagulation,
correction of disorder of renal lipid mediator (thromboxane
A2 hyperproduction state), inhibition of inﬁltration of
macrophage to glomerulus based on inhibitory action on
cytokine production, restoration of steroid-responsiveness,
and enhancement of intracellular incorporation of cocurrent
use of cyclosporine.
(2) Selesorb. By inmmunoabsorption therapy with Selesorb,
the mean removal rate of anti-DNA antibody was 34%,
moreover, anticardiolipin antibody and immune complex
were eﬃciently removed. The clinical features of systemic
lupus erythematosus, such as facial erythema and hemato-
logic disorder, were also improved without severe adverse
eﬀects [38].
5. Conclusion
It is important that blood puriﬁcation therapy should be
performed consistently evaluating not only risks associated
withthesebioincompatibilitiesbutalsoloadstocardiovascu-
lar system posed by extracorporeal circulation, risks relating
to vascular access creation, and exacerbation of hemorrhagic
tendency caused by anticoagulant, together with advantages
obtained from treatments. The characteristics of biocompat-
ibility of each material mentioned here will bring important
information for safer blood puriﬁcation therapy.
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